Acetylcholinesterase inhibitors represent one of the most critical classes of pharmacotherapeutic and biochemical agents within neurobiology, clinical neurology, and toxicology. By preventing the enzymatic degradation of the vital neurotransmitter acetylcholine, these compounds modulate synaptic signaling throughout both the central and peripheral nervous systems. Understanding the precise biochemical kinetics, clinical indications, and toxicological profiles of these agents is essential for comprehending modern interventions in neurodegenerative conditions and neuromuscular disorders.
Acetylcholinesterase Inhibitor (AChEI)
1. Concise Definition
An acetylcholinesterase inhibitor (AChEI), commonly referred to as a cholinesterase inhibitor, is a chemical substance or pharmaceutical agent that binds to and suppresses the hydrolytic activity of the enzyme acetylcholinesterase (AChE). By inhibiting this enzyme, the agent prevents the breakdown of the neurotransmitter acetylcholine (ACh) into acetate and choline, thereby prolonging the duration and increasing the concentration of acetylcholine within the synaptic cleft.
Functionally, AChEIs amplify cholinergic neurotransmission at both nicotinic and muscarinic receptor sites throughout the peripheral and central nervous systems. Depending on their molecular design, chemical affinity, and stability of the enzyme-inhibitor complex, these agents are classified as reversible, pseudo-irreversible, or irreversible. Clinically, reversible inhibitors are deployed to mitigate symptoms of cognitive decline in neurodegenerative diseases such as Alzheimer's disease and to restore muscle function in autoimmune conditions like myasthenia gravis, whereas irreversible variants are primarily encountered in industrial pesticides and chemical warfare agents.
2. Etymology & Linguistic Origin
The term acetylcholinesterase inhibitor is a composite biomedical descriptor rooted in classical Greek, Latin, and modern biochemical nomenclature. The prefix acetyl- originates from the Latin acetum (meaning vinegar), reflecting the two-carbon acetic acid moiety. The root choline derives from the Greek cholē (χολή, meaning bile), so named because the organic base was first isolated from ox bile by German chemist Adolph Strecker in 1862. The suffix -ester was coined by German chemist Leopold Gmelin in the nineteenth century as an abbreviation of Essigäther (acetic ether), denoting the chemical linkage between an acid and an alcohol.
The suffix -ase, standard in enzymology, derives from the Greek diastasis (διάστασις, meaning separation). Finally, inhibitor stems from the Latin verb inhibere, composed of in- (in, upon) and habere (to hold), literally translating to 'to hold back, restrain, or curb.' Thus, the term etymologically designates a compound that holds back the catalytic enzyme responsible for breaking down the acetic ester of choline.
3. Pronunciation & Grammatical Form
Pronunciation: /əˌsiːtəlˌkoʊlɪnˈɛstəreɪs ɪnˈhɪbɪtər/ (US: uh-SEE-tuhl-koh-lih-NES-tuh-rayss in-HIB-ih-ter).
Grammatical Form: Compound noun phrase (countable). Plural: acetylcholinesterase inhibitors. Commonly abbreviated as AChEI or AChEIs in professional medical and neurochemical literature. It may also function attributively as a noun adjunct, as in 'acetylcholinesterase inhibitor therapy' or 'AChEI-induced cholinergic crisis.'
4. Detailed Conceptual Explanation
To fully grasp the mechanism of an acetylcholinesterase inhibitor, one must first examine the physiological role of acetylcholinesterase in neurotransmission. Acetylcholine is a primary neurotransmitter operating at the neuromuscular junction, the autonomic ganglia, postganglionic parasympathetic neuroeffector junctions, and multiple projecting pathways within the central nervous system. Following vesicular exocytosis into the synaptic cleft, acetylcholine binds to ligand-gated nicotinic acetylcholine receptors (nAChRs) or G-protein coupled muscarinic acetylcholine receptors (mAChRs) to propagate depolarization or intracellular signaling cascades.
Under baseline physiological conditions, signal transmission must be terminated with exceptional speed to allow rapid repolarization and subsequent signaling. Acetylcholinesterase is one of nature's most catalytically efficient enzymes, capable of hydrolyzing approximately 25,000 molecules of acetylcholine per second per active site—approaching the theoretical limit of diffusion-controlled reaction kinetics. The catalytic machinery of the enzyme features an active site situated at the base of a 20-angstrom-deep gorge, consisting of an esteratic subsite (containing the catalytic triad Ser200, His440, and Glu327) and an aromatic, peripheral anionic subsite (PAS) that guides the positively charged quaternary amine of acetylcholine into the catalytic core.
An acetylcholinesterase inhibitor disrupts this process by directly occupying the active site gorge, the catalytic triad, or the peripheral anionic site. When an inhibitor binds, it blocks access to endogenous acetylcholine. As a consequence, acetylcholine molecules remain intact within the synapse for an extended duration, accumulating to supra-physiological concentrations. This prolonged residency time leads to repetitive and sustained activation of postsynaptic and presynaptic cholinergic receptors, effectively amplifying cholinergic tone throughout the target tissue.
The boundaries of AChEI activity are defined by the pharmacodynamic reversibility of this enzyme-inhibitor complex. Reversible inhibitors participate in rapid equilibrium binding governed by standard non-covalent interactions (van der Waals, hydrogen bonding, π-π stacking). Pseudo-reversible carbamate agents form a covalent bond with the catalytic serine residue; however, this carbamylated enzyme undergoes slow spontaneous hydrolysis over several hours, eventually restoring enzymatic function. In stark contrast, irreversible organophosphate compounds phosphorylate the serine hydroxyl group and can undergo an intramolecular chemical reaction termed 'aging,' in which the loss of an alkyl side chain renders the covalent bond practically permanent without the prompt application of an oxime reactivator.
5. Historical Development
The history of acetylcholinesterase inhibition spans more than a century of organic chemistry, colonial ethnobotany, modern neuropharmacology, and toxicological warfare. The earliest recognized AChEI was physostigmine (eserine), an alkaloid isolated from the Calabar bean (Physostigma venenosum), indigenous to West Africa, where it was traditionally utilized in judicial trials by ordeal. In 1864, Sir Arthur Christison and Jobst and Hesse characterized the compound, and by 1877, Ludwig Laqueur introduced physostigmine into ophthalmology to treat glaucoma by reducing intraocular pressure.
In the 1930s, Scottish physician Mary Broadfoot Walker made a revolutionary clinical discovery. Recognizing the symptomatic parallels between curare poisoning and myasthenia gravis, she administered physostigmine—and later the synthetic analogue neostigmine—to a myasthenic patient, demonstrating rapid and dramatic reversal of ptosis and muscular weakness. Walker's breakthrough established acetylcholinesterase inhibition as the gold standard of care for autoimmune myasthenia gravis.
Concurrently, during the late 1930s and 1940s, German chemist Gerhard Schrader investigated synthetic organophosphorus compounds for the chemical conglomerate IG Farben. While developing high-potency agricultural insecticides, Schrader discovered potent organophosphate AChEIs, leading directly to the state-sponsored synthesis of deadly G-series nerve agents, including tabun, sarin, and soman. These discoveries illustrated the catastrophic lethal potential of irreversible cholinesterase blockade.
In the late twentieth century, the conceptual landscape of AChEIs expanded into cognitive neurology. The emergence of the 'cholinergic hypothesis of geriatric memory dysfunction' formulated by Peter Davies, David Treanor, and colleagues in the late 1970s linked the profound cognitive decline of Alzheimer's disease to a selective loss of cholinergic projection neurons in the basal forebrain (nucleus basalis of Meynert). This finding initiated a major pharmaceutical effort that culminated in the 1993 FDA approval of tacrine, the first centrally active AChEI for Alzheimer's disease. Although tacrine was later abandoned due to hepatotoxicity, it paved the way for modern, better-tolerated agents such as donepezil (approved 1996), rivastigmine (approved 2000), and galantamine (approved 2001).
6. Theoretical Foundations
The primary theoretical framework supporting the clinical utility of AChEIs in neurodegenerative pathology is the Cholinergic Hypothesis of Alzheimer's Disease. This paradigm posits that the progressive degeneration of ascending cholinergic pathways originating in the basal forebrain—and projecting widely to the cerebral cortex and hippocampus—underlies the profound memory consolidation failures, attentional deficits, and spatial disorientation observed in dementia. Because acetylcholine is instrumental in synaptic plasticity, long-term potentiation (LTP), and cortical processing, boosting the signaling lifespan of surviving cholinergic terminals via enzymatic inhibition provides compensatory symptomatic improvement.
A second foundational framework is the Biophysical Model of Neuromuscular Transmission. At the motor endplate, a wide margin of safety exists under healthy conditions; the quantity of acetylcholine released from a presynaptic action potential far exceeds the threshold required to trigger a muscle action potential. In myasthenia gravis, autoantibodies against the nicotinic acetylcholine receptor or muscle-specific kinase (MuSK) severely deplete functional receptor density, compromising this safety factor and causing muscle weakness and pathognomonic fatigue. Pharmacological inhibition of AChE restores the safety factor by ensuring that acetylcholine persists long enough to repeatedly bind the remaining receptor pool, maintaining transmission fidelity.
Finally, enzyme kinetics theory—specifically Michaelis-Menten kinetics and allosteric modulation dynamics—informs the structural biology of AChEIs. Modern crystallographic studies demonstrate that AChE features distinct binding microdomains, including the peripheral anionic site (PAS) at the surface and the acylation site at the base. Recent neurochemical theories focus on dual-binding-site inhibitors that bridge both the PAS and the active site, positing that such interactions not only potentiate cholinergic neurotransmission but may also inhibit the PAS-induced aggregation of amyloid-beta fibrils, linking enzyme pharmacology directly to disease-modifying hypotheses.
7. Key Components, Types & Dimensions
Acetylcholinesterase inhibitors are categorized across structural, kinetic, and pharmacodynamic dimensions:
- Reversible Competitive/Non-Competitive Inhibitors: Compounds that bind non-covalently to the active site or peripheral anionic site. They rapidly dissociate from the enzyme, establishing a concentration-dependent equilibrium. Examples include:
- Donepezil: A piperidine derivative that reversibly and selectively inhibits AChE with high affinity, crossing the blood-brain barrier with minimal affinity for peripheral butyrylcholinesterase.
- Galantamine: A tertiary phenanthrene alkaloid exhibiting a dual mechanism: competitive AChE inhibition and positive allosteric modulation of nicotinic acetylcholine receptors.
- Edrophonium: A short-acting quaternary ammonium compound used historically in diagnostic challenge testing due to its rapid onset and brief duration of action (minutes).
- Pseudo-Irreversible (Carbamate) Inhibitors: Molecules that undergo catalytic cleavage by AChE, transferring a carbamoyl moiety to the active-site serine residue. The resulting carbamylated enzyme undergoes slow decarbamylation (measured in hours), prolonging the inhibitory state:
- Rivastigmine: A pseudo-irreversible carbamate that inhibits both acetylcholinesterase and butyrylcholinesterase (BuChE) in the central nervous system.
- Neostigmine & Pyridostigmine: Quaternary ammonium carbamates that do not meaningfully cross the blood-brain barrier, making them ideal for treating peripheral disorders like myasthenia gravis without central adverse effects.
- Physostigmine: A tertiary amine carbamate that penetrates the central nervous system, historically used to treat central anticholinergic toxicity.
- Irreversible Organophosphates: Highly toxic compounds that covalently phosphorylate the catalytic serine hydroxyl group. The covalent enzyme-phosphate bond is resistant to spontaneous hydrolysis:
- Chemical Warfare Agents: Volatile neurotoxins including sarin (GB), soman (GD), tabun (GA), and VX, engineered for maximum lethality via widespread systemic cholinergic crisis.
- Agricultural Insecticides: Compounds such as malathion, parathion, and chlorpyrifos, which cause prolonged intoxication upon accidental or occupational exposure.
- Echothiophate: An organophosphate previously employed in ophthalmic solutions to induce persistent miosis and decrease intraocular pressure in refractory glaucoma.
8. Examples & Illustrative Cases
The practical application of acetylcholinesterase inhibitors can be illustrated through distinct clinical vignettes spanning neurology, critical care, and emergency toxicology.
Case Illustration 1: Management of Neurodegenerative Cognitive Decline
A 74-year-old retired architect presents with a two-year history of insidious, progressive memory loss, spatial disorientation, and difficulty executing complex executive functions. Neuropsychological evaluation reveals a Mini-Mental State Examination (MMSE) score of 21/30, and structural magnetic resonance imaging (MRI) reveals bilateral hippocampal atrophy out of proportion to global involution, confirming mild-to-moderate Alzheimer's disease. The neurologist initiates therapy with donepezil at 5 mg daily, escalating to 10 mg after six weeks. Over the subsequent six months, repeat cognitive evaluations demonstrate stabilization of MMSE scores at 22/30, with the patient's family reporting improved daytime alertness, greater engagement in conversational dialogue, and a reduction in apathy. The AChEI successfully slowed the apparent rate of cognitive degradation by compensating for ongoing basal forebrain cholinergic cell loss.
Case Illustration 2: Reversal of Autoimmune Myasthenic Crisis
A 32-year-old female presents with fluctuating diplopia, bilateral ptosis that worsens toward the evening, and difficulty chewing solid food. Electromyography reveals significant decremental responses to repetitive nerve stimulation at 3 Hz, and serum testing confirms elevated anti-acetylcholine receptor (AChR) antibodies, confirming generalized myasthenia gravis. She is prescribed pyridostigmine bromide at 60 mg orally every four hours. Within 45 minutes of each dose, her ptosis resolves, her voice regains volume, and her swallowing difficulties dissipate. The AChEI counterbalances the loss of available nicotinic receptors at the neuromuscular junction by maintaining elevated synaptic levels of acetylcholine.
Case Illustration 3: Acute Organophosphate Toxicity and Resuscitation
A 45-year-old agricultural worker is transported to the emergency department following an accidental spill of concentrated chlorpyrifos insecticide. The patient is found comatose, exhibiting profound diaphoresis, diffuse muscle fasciculations, pinpoint pupils (miosis), severe bradycardia, urinary incontinence, and copious bronchorrhea. The clinical team identifies acute cholinergic toxicity resulting from irreversible acetylcholinesterase inhibition. Treatment is initiated immediately with intravenous atropine to competitively block muscarinic receptors and halt respiratory compromise, followed by the oxime pralidoxime (2-PAM) to nucleophilically reactivate the phosphorylated acetylcholinesterase before irreversible aging occurs.
9. Measurement & Assessment
Assessing acetylcholinesterase activity and the physiological impact of its inhibitors involves both direct biochemical assays and indirect clinical monitoring:
- Ellman's Colorimetric Assay: The global standard laboratory technique for quantifying acetylcholinesterase and butyrylcholinesterase activity. The assay utilizes acetylthiocholine as an alternative substrate; cleavage yields thiocholine, which reacts with 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB or Ellman's reagent) to produce a yellow 5-thio-2-nitrobenzoate anion, measured spectrophotometrically at 412 nm.
- Red Blood Cell (RBC) Cholinesterase vs. Serum Pseudocholinesterase: In clinical toxicology and occupational health surveillance, erythrocyte AChE activity is monitored because RBC cholinesterase is chemically identical to neuronal acetylcholinesterase, serving as a reliable surrogate marker of neurological target inhibition. Plasma/serum pseudocholinesterase (butyrylcholinesterase) serves as a sensitive, rapid-response marker of exposure, though it correlates less directly with neural enzyme status.
- Standardized Neuropsychological Batteries: In dementia management, AChEI therapeutic efficacy is tracked using serial psychometric instruments, including the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), and the Montreal Cognitive Assessment (MoCA).
- Electrophysiological Testing: In neuromuscular settings, repetitive nerve stimulation (RNS) and single-fiber electromyography (SFEMG) quantify jitter and neuromuscular transmission failure, monitoring therapeutic normalization following AChEI administration.
10. Applications & Practical Significance
The applications of acetylcholinesterase inhibitors extend across diverse medical and pharmacological domains:
In Cognitive Neurology, centrally acting AChEIs (donepezil, rivastigmine, galantamine) remain the primary initial pharmacological treatment for mild-to-moderate Alzheimer's disease, Lewy body dementia, and Parkinson's disease dementia. While these agents do not halt the underlying neurodegenerative process, they provide modest, measurable symptomatic gains in attention, working memory, and behavioral functioning.
In Neuromuscular Medicine, peripheral AChEIs like pyridostigmine and neostigmine serve as foundational symptomatic therapies for myasthenia gravis and congenital myasthenic syndromes that do not involve baseline endplate AChE deficiency. Furthermore, neostigmine and sugammadex are standard in anesthesiology for the reversal of non-depolarizing neuromuscular blockade (such as that induced by rocuronium or vecuronium) at the conclusion of surgical procedures.
In Clinical Toxicology, physostigmine serves as a specific antidote for central anticholinergic toxicity caused by overdoses of atropine, scopolamine, diphenhydramine, or tricyclic antidepressants. By crossing the blood-brain barrier, physostigmine restores central cholinergic transmission and alleviates delirium, hyperthermia, and tachycardia.
11. Research & Empirical Evidence
Extensive randomized controlled trials (RCTs) and systematic meta-analyses have characterized the efficacy and limitations of AChEIs across clinical indications. Landmark Cochrane systematic reviews evaluating donepezil, galantamine, and rivastigmine in Alzheimer's disease (Birks, 2006; Birks & Harvey, 2018) synthesized data from dozens of double-blind, placebo-controlled trials. The findings consistently show statistically significant benefits in cognitive performance (average improvement of 1.5 to 2.5 points on the ADAS-Cog scale) and modest improvements in activities of daily living and global clinical ratings over 6- to 12-month periods compared to placebo.
However, these empirical reviews emphasize the heterogeneity of clinical response: while a subset of patients exhibits noticeable temporary improvement or prolonged functional stabilization, others show minimal benefit. Long-term observational studies suggest that after 12 to 24 months, underlying disease progression generally overtakes the symptomatic improvements provided by AChEIs, returning patients to their pre-treatment trajectories.
In the domain of Lewy body dementias, double-blind trials conducted by McKeith and colleagues demonstrated that AChEIs often produce larger improvements in neuropsychiatric features—specifically visual hallucinations, apathy, and fluctuating attention—than in classic Alzheimer's dementia, reflecting the more severe cholinergic deficit present in Lewy body pathologies. Modern research is also exploring dual-target ligands (hybrids combining AChEI activity with beta-secretase inhibition or antioxidant moieties) and intranasal delivery formulations designed to maximize central bioavailability while minimizing peripheral adverse effects.
12. Cultural & Cross-Cultural Considerations
Perceptions, availability, and utilization patterns of acetylcholinesterase inhibitors differ widely across cultural and socioeconomic contexts. In high-income healthcare systems, AChEIs have long been integrated into standard clinical algorithms as routine primary therapies for neurocognitive disorders, accompanied by substantial third-party reimbursement and caregiver expectations of proactive medical management.
Conversely, in many low- and middle-income countries (LMICs), access to specialized diagnostic infrastructure (such as cognitive testing, amyloid biomarker profiling, and neuroimaging) is limited. In these regions, neurodegenerative disorders may be viewed as normal senescence or supernatural phenomena rather than treatable medical conditions, leading to delayed diagnoses and low rates of AChEI prescription. Furthermore, out-of-pocket costs for branded formulations remain a major barrier to adherence in low-resource environments.
Cross-cultural differences also emerge in toxicology. In rural agricultural regions across South Asia, Southeast Asia, and Central America, intentional and accidental organophosphate poisoning represents a major public health challenge. Cultural practices surrounding pesticide storage, agricultural regulation, and the availability of emergency resuscitation infrastructure directly influence survival rates from acute irreversible AChEI toxicity.
13. Criticisms, Debates & Limitations
Despite their widespread clinical use, acetylcholinesterase inhibitors are subject to several persistent debates and therapeutic limitations:
Symptomatic vs. Disease-Modifying Efficacy: The primary criticism of AChEIs in neurodegenerative care is that they are purely symptomatic. They do not halt the misfolding and aggregation of tau or amyloid-beta proteins, nor do they prevent the eventual loss of cortical neurons. This limitation has fueled debates regarding cost-effectiveness and prompted the development of newer disease-modifying therapies, such as anti-amyloid monoclonal antibodies.
Peripheral Adverse Effect Profile: The systemic accumulation of acetylcholine frequently triggers dose-limiting adverse events. Activation of gastrointestinal muscarinic receptors causes nausea, vomiting, diarrhea, abdominal cramping, and anorexia, often leading to therapy discontinuation. Activation of cardiac muscarinic receptors can induce sinus bradycardia, heart block, and syncope—a significant risk in older adults with pre-existing conduction disorders that can lead to falls and fractures.
Cholinergic Crisis vs. Myasthenic Crisis: In neuromuscular medicine, managing AChEIs involves a narrow therapeutic window. Overtreatment can induce a 'cholinergic crisis,' in which excessive acetylcholine depolarizes the neuromuscular endplate continuously, triggering flaccid muscle paralysis that clinically mimics a worsening myasthenic crisis. Differentiating between insufficient and excessive AChEI administration remains a critical diagnostic challenge.
14. Related Terms & Distinctions
To avoid conceptual and clinical confusion, acetylcholinesterase inhibitors should be distinguished from several related pharmacological classes:
- Butyrylcholinesterase (BuChE) Inhibitors: Butyrylcholinesterase (also known as pseudocholinesterase) is synthesized in the liver and found in plasma, glial cells, and smooth muscle. While AChE preferentially hydrolyzes acetylcholine, BuChE acts on a broader array of choline and non-choline esters. Certain agents, like rivastigmine, inhibit both enzymes, whereas donepezil is highly selective for AChE.
- Direct Cholinergic Agonists: Molecules that directly bind to and activate muscarinic or nicotinic receptors (e.g., bethanechol, pilocarpine, nicotine), bypassing the acetylcholinesterase enzyme entirely. In contrast, AChEIs act indirectly by preserving endogenous acetylcholine.
- NMDA Receptor Antagonists: Agents such as memantine that regulate glutamatergic neurotransmission by blocking pathologically excessive NMDA receptor excitotoxicity. Memantine operates through an entirely different neurotransmitter pathway and is frequently co-prescribed with AChEIs for synergistic therapeutic effects in moderate-to-severe dementia.
- Anticholinergics: Pharmacological antagonists that block acetylcholine receptors (e.g., atropine, scopolamine, benztropine). Anticholinergics produce the direct opposite physiological effects of AChEIs and are used clinically to manage AChEI intoxication.
15. Summary / Key Takeaways
Acetylcholinesterase inhibitors (AChEIs) are essential pharmacological tools that elevate and prolong endogenous acetylcholine activity across the central and peripheral nervous systems. Structurally diverse—spanning short-acting competitive inhibitors, pseudo-irreversible carbamates, and lethal irreversible organophosphates—these agents are indicated for conditions characterized by cholinergic deficits, such as Alzheimer's disease and myasthenia gravis. While their efficacy in dementia is primarily symptomatic and constrained by peripheral cholinergic adverse effects, AChEIs remain foundational in modern neurology, anesthesiology, and toxicology.
In summary, acetylcholinesterase inhibitors highlight the delicate relationship between therapeutic neuromodulation and toxicological crisis. By calibrating the activity of one of the body's fastest enzymes, AChEIs can restore cognitive and neuromuscular function when used appropriately, but can cause severe systemic toxicity when unregulated. Continued research into selective, dual-acting, and brain-targeted formulations aims to refine their benefits while minimizing peripheral complications across diverse patient populations.
References
- Birks, J. S. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews, (1), CD005593. https://doi.org/10.1002/14651858.CD005593
- Birks, J. S., & Harvey, R. J. (2018). Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews, 6(6), CD001190. https://doi.org/10.1002/14651858.CD001190.pub3
- Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013). Acetylcholinesterase inhibitors: Pharmacology and toxicology. Current Neuropharmacology, 11(3), 315–335. https://doi.org/10.2174/1570159X11311030006
- Davies, P., & Maloney, A. J. (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. The Lancet, 308(8000), 1403. https://doi.org/10.1016/S0140-6736(76)91936-X
- Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991). Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein. Science, 253(5022), 872–879. https://doi.org/10.1126/science.1678899